Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
NCT04379050
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
130
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease (PD)
Interventions
DRUG:
ABBV-951
Sponsor
AbbVie